help button home button Am J Pathol Epitomics, Inc.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wallenius, V.
Right arrow Articles by Jansson, J.-O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wallenius, V.
Right arrow Articles by Jansson, J.-O.
(American Journal of Pathology. 2000;156:821-829.)
© 2000 American Society for Investigative Pathology


Regular Articles

Overexpression of the Hepatocyte Growth Factor (HGF) Receptor (Met) and Presence of a Truncated and Activated Intracellular HGF Receptor Fragment in Locally Aggressive/Malignant Human Musculoskeletal Tumors

Ville Wallenius*, Masanori Hisaoka{dagger}, Khalil Helou{ddagger}, Göran Levan{ddagger}, Nils Mandahl§, Jeanne M. Meis-Kindblom{dagger}, Lars-Gunnar Kindblom{dagger} and John-Olov Jansson*

From the Research Center for Endocrinology and Metabolism (RCEM), Department of Internal Medicine,*
and Gothenburg Musculoskeletal Tumor Center, Department of Pathology,{dagger}
Sahlgrenska University Hospital, Gothenburg; the Department of Cell and Molecular Biology,{ddagger}
University of Gothenburg, Gothenburg; and the Department of Clinical Genetics,§
University Hospital, Lund, Sweden

Enhanced hepatocyte growth factor (HGF) receptor (Met) signaling has been suggested to play an important role in the development and progression of various epithelial and nonepithelial tumors. N-terminally truncated forms of the HGF receptor have been shown to be constitutively activated and tumorigenic in animal experiments. In the present study, 102 benign and malignant human musculoskeletal tumors were examined for expression of the HGF receptor by Western blotting and/or immunohistochemistry. A clear predominance of HGF receptor expression was seen in malignant as compared to benign tumors (Western blotting, P < 0.001; immunohistochemistry, P < 0.02). For the first time we show HGF receptor expression in the following four tumor types: dermatofibrosarcoma protuberans, clear cell sarcoma of tendons, malignant primitive neuroectodermal tumor, and benign fibrous histiocytoma. In three cases of sarcoma with high HGF receptor expression by Western blotting, we found indications of a short 85-kd N-terminally truncated HGF receptor that was tyrosine phosphorylated and located in the cytoplasm. Although fragments of this length were seen in 18 of 65 tumors, most were not tyrosine-phosphorylated. Northern blotting revealed only the 7.5-kb full-length HGF receptor transcript, suggesting that the 85-kd fragment is generated by an alternative initiation of translation or by proteolytic cleavage. Southern blotting detected no amplification of the Hgfr/Met gene in the 35 tumors examined, in contrast to our recent report of Hgfr/Met gene amplification in 7,12-dimethylbenz(a)anthracene (DMBA)-induced rat sarcomas. The present data suggest that the locally aggressive and malignant properties of human mesenchymal tumors maybe related, in part, to high levels of full-length HGF receptors, and in some cases to the occurrence of N-terminally truncated HGF receptors, activated independently of HGF.





This article has been cited by other articles:


Home page
Cancer Res.Home page
I. J. Davis, A. W. McFadden, Y. Zhang, A. Coxon, T. L. Burgess, A. J. Wagner, and D. E. Fisher
Identification of the Receptor Tyrosine Kinase c-Met and Its Ligand, Hepatocyte Growth Factor, as Therapeutic Targets in Clear Cell Sarcoma
Cancer Res., January 15, 2010; 70(2): 639 - 645.
[Abstract] [Full Text] [PDF]


Home page
Veterinary PathologyHome page
H. Fieten, B. Spee, J. IJzer, M. J. Kik, L. C. Penning, and J. Kirpensteijn
Expression of Hepatocyte Growth Factor and the Proto-oncogenic Receptor c-Met in Canine Osteosarcoma
Veterinary Pathology, September 1, 2009; 46(5): 869 - 877.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
M. Lerdrup, S. Bruun, M. V. Grandal, K. Roepstorff, M. M. Kristensen, A. M. Hommelgaard, and B. van Deurs
Endocytic Down-Regulation of ErbB2 Is Stimulated by Cleavage of Its C-Terminus
Mol. Biol. Cell, September 1, 2007; 18(9): 3656 - 3666.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
S. Hiscox, N. J Jordan, W. Jiang, M. Harper, R. McClelland, C. Smith, and R. I Nicholson
Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions
Endocr. Relat. Cancer, December 1, 2006; 13(4): 1085 - 1099.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
N. Riggi, L. Cironi, P. Provero, M.-L. Suva, J.-C. Stehle, K. Baumer, L. Guillou, and I. Stamenkovic
Expression of the FUS-CHOP Fusion Protein in Primary Mesenchymal Progenitor Cells Gives Rise to a Model of Myxoid Liposarcoma.
Cancer Res., July 15, 2006; 66(14): 7016 - 7023.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
G. Athauda, A. Giubellino, J. A. Coleman, C. Horak, P. S. Steeg, M.-J. Lee, J. Trepel, J. Wimberly, J. Sun, A. Coxon, et al.
c-Met Ectodomain Shedding Rate Correlates with Malignant Potential.
Clin. Cancer Res., July 15, 2006; 12(14): 4154 - 4162.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Patane, S. Avnet, N. Coltella, B. Costa, S. Sponza, M. Olivero, E. Vigna, L. Naldini, N. Baldini, R. Ferracini, et al.
MET Overexpression Turns Human Primary Osteoblasts into Osteosarcomas.
Cancer Res., May 1, 2006; 66(9): 4750 - 4757.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
D. S. Krause and R. A. Van Etten
Tyrosine Kinases as Targets for Cancer Therapy
N. Engl. J. Med., July 14, 2005; 353(2): 172 - 187.
[Full Text] [PDF]


Home page
Cancer Res.Home page
Z. Lou, S. O'Reilly, H. Liang, V. M. Maher, S. D. Sleight, and J. J. McCormick
Down-Regulation of Overexpressed Sp1 Protein in Human Fibrosarcoma Cell Lines Inhibits Tumor Formation
Cancer Res., February 1, 2005; 65(3): 1007 - 1017.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. Liu, X.-Z. Yu, T.-S. Li, L.-X. Song, P.-L. Chen, T.-L. Suo, Y.-H. Li, S.-D. Wang, Y. Chen, Y.-M. Ren, et al.
A Novel Protein Tyrosine Kinase NOK that Shares Homology with Platelet- Derived Growth Factor/Fibroblast Growth Factor Receptors Induces Tumorigenesis and Metastasis in Nude Mice
Cancer Res., May 15, 2004; 64(10): 3491 - 3499.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
M. P. Paronetto, D. Farini, I. Sammarco, G. Maturo, G. Vespasiani, R. Geremia, P. Rossi, and C. Sette
Expression of a Truncated Form of the c-Kit Tyrosine Kinase Receptor and Activation of Src Kinase in Human Prostatic Cancer
Am. J. Pathol., April 1, 2004; 164(4): 1243 - 1251.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Y. Kang, M. Dolled-Filhart, I. T. Ocal, B. Singh, C.-Y. Lin, R. B. Dickson, D. L. Rimm, and R. L. Camp
Tissue Microarray Analysis of Hepatocyte Growth Factor/Met Pathway Components Reveals a Role for Met, Matriptase, and Hepatocyte Growth Factor Activator Inhibitor 1 in the Progression of Node-negative Breast Cancer
Cancer Res., March 1, 2003; 63(5): 1101 - 1105.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
N. Chattopadhyay, R. J. MacLeod, J. Tfelt-Hansen, and E. M. Brown
1alpha ,25(OH)2-vitamin D3 inhibits HGF synthesis and secretion from MG-63 human osteosarcoma cells
Am J Physiol Endocrinol Metab, January 1, 2003; 284(1): E219 - E227.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
P. L. Peghini, M. Iwamoto, M. Raffeld, Y.-J. Chen, S. U. Goebel, J. Serrano, and R. T. Jensen
Overexpression of Epidermal Growth Factor and Hepatocyte Growth Factor Receptors in a Proportion of Gastrinomas Correlates with Aggressive Growth and Lower Curability
Clin. Cancer Res., July 1, 2002; 8(7): 2273 - 2285.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Walentinsson, K. Helou, V. Wallenius, H. J. Hedrich, C. Szpirer, and G. Levan
Independent Amplification of Two Gene Clusters on Chromosome 4 in Rat Endometrial Cancer: Identification and Molecular Characterization
Cancer Res., November 1, 2001; 61(22): 8263 - 8273.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American Society for Investigative Pathology.